Mengting Li

Ms. Mengting Li


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MLMengting Li
Mengting Li
FTFan Tong
Fan Tong
BWBian Wu
Bian Wu
XDXiaorong Dong
Xiaorong Dong
Radiation therapy is widely recognized as an efficacious modality for treating neoplasms located within the craniofacial region. Nevertheless, this approach is not devoid of risks, predominantly concerning potential harm to the neural structures. Adverse effects may encompass focal cerebral necrosis, cognitive function compromise, cerebrovascular pathology, spinal cord injury, and detriment to the neural fibers constituting the brachial plexus. With increasing survival rates among oncology patients, evaluating post-treatment quality of life has become crucial in assessing the benefits of radiation therapy. Consequently, it is imperative to investigate therapeutic strategies to mitigate cerebral complications from radiation exposure. Current management of radiation-induced cerebral damage involves corticosteroids and bevacizumab, with preclinical research on antioxidants and thalidomide. Despite these efforts, an optimal treatment remains elusive. Recent studies suggest the gut microbiota’s involvement in neurologic pathologies. This review aims to discuss the causes and existing treatments for radiation-induced cerebral injury and explore gut microbiota modulation as a potential therapeutic strategy.

4 October 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
BWBian Wu
Bian Wu
MLMengting Li
Mengting Li
PDPeng Ding
Peng Ding
HTHaoyue Tan
Haoyue Tan
ZZZiqi Zhang
Ziqi Zhang
XDXiaorong Dong
Xiaorong Dong
Premature terminated clinical trials waste resources, burden patients, and hinder scientific progress. The extent of discontinuation of radiotherapy trials is largely unknown. This study analyzed the reasons, prevalence, and characteristics of discontinued radiotherapy trials registered on ClinicalTrials.gov. Oncology trials registered between June 1, 2014, and June 1, 2024, were categorized as radiotherapy or other oncology trials. Discontinuation rates and reasons were compared. Multivariable logistic regression was fitted to identify predictors of radiotherapy trial discontinuation. Of 35,402 trials, 1799 (5.1 %) were radiotherapy trials. Radiotherapy trials had a lower termination/withdrawal rate than other oncology trials (8.6 % vs. 12.8 %; p < 0.001). An analysis of reported reasons for trial discontinuation showed that radiotherapy trials were more prone to termination because of insufficient enrollment (58.7 % [95 % CI, 50.8 %-66.2 %] vs. 27.1 % [95 % CI, 25.8 %-28.5 %]; p < 0.001) and less likely to end because of business/sponsor decisions (1.9 % [95 % CI, 0.5 %-5.5 %] vs. 20.0 %[95 % CI, 18.8 %-21.2 %]; p < 0.001) compared to other oncology trials. Predictors of radiotherapy trial discontinuation included parallel groups (odds ratio [OR], 4.06; p < 0.001), National Institutes of Health sponsorship (OR, 3.85; p = 0.008), and academic institution sponsorship (OR, 3.17; p = 0.003). Trials conducted at multiple sites (OR, 0.49; p = 0.010), in Asia (OR, 0.16; p < 0.001), and in Europe (OR, 0.51; p = 0.019) were more likely to be completed. Nearly 60 % of the radiotherapy trials terminated due to poor accrual. Radiotherapy trials failure was associated with funding, location, and study design. Targeted efforts are needed to promote trial completion and strengthen evidence-based radiation oncology.